Paper · 41789112
Decoding lung-kidney interactions in sepsis: an integrated view of molecular mechanisms, pathophysiology, and therapeutic interventions.
Ma C and 10 others. Front Immunol, 2026. Cited by 1 paper, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Decoding lung-kidney interactions in sepsis: an integrated view of molecular mechanisms, pathophysiology, and therapeutic interventions. Papers, record 41789112. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41789112
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Decoding lung-kidney interactions in sepsis: an integrated view of molecular mechanisms, pathophysiology, and therapeutic interventions.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sepsis | Major topic |
| Lung | Major topic |
| Kidney | Major topic |
| Humans | |
| Animals |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References188
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26,276,375 | Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: A case-control study. | Cytokine | 2015 | https://conductscience.org/library/papers/26276375 | PubMed |
| 2 | 27,648,691 | The Predictive Value of Plasma Galectin-3 for Ards Severity and Clinical Outcome. | Shock | 2017 | https://conductscience.org/library/papers/27648691 | PubMed |
| 3 | 37,667,081 | Interorgan communication networks in the kidney-lung axis. | Nat Rev Nephrol | 2024 | https://conductscience.org/library/papers/37667081 | PubMed |
| 4 | 9,389,739 | Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. | J Clin Invest | 1997 | https://conductscience.org/library/papers/9389739 | PubMed |
| 5 | 24,335,445 | Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*. | Crit Care Med | 2014 | https://conductscience.org/library/papers/24335445 | PubMed |
| 6 | 31,454,263 | Balanced Crystalloids versus Saline in Sepsis. A Secondary Analysis of the SMART Clinical Trial. | Am J Respir Crit Care Med | 2019 | https://conductscience.org/library/papers/31454263 | PubMed |
| 7 | 17,497,449 | Acute effects of intermittent hemodialysis and sustained low-efficiency hemodialysis (SLED) on the pulmonary function of patients under mechanical ventilation. | Ren Fail | 2007 | https://conductscience.org/library/papers/17497449 | PubMed |
| 8 | 39,064,059 | Clinical and Experimental Evidence for Patient Self-Inflicted Lung Injury (P-SILI) and Bedside Monitoring. | J Clin Med | 2024 | https://conductscience.org/library/papers/39064059 | PubMed |
| 10 | 32,468,087 | Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial. | Intensive Care Med | 2020 | https://conductscience.org/library/papers/32468087 | PubMed |
| 11 | 18,074,478 | Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. | Crit Care Med | 2007 | https://conductscience.org/library/papers/18074478 | PubMed |
1 to 10 of 188
See all 188 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
None in this release.
Genes78
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ADH1A | 124 | PubTator's text mining | https://conductscience.org/library/genes/124 | NCBI Gene |
| ADM | 133 | PubTator's text mining | https://conductscience.org/library/genes/133 | NCBI Gene |
| AHR | 196 | PubTator's text mining | https://conductscience.org/library/genes/196 | NCBI Gene |
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| ANPEP | 290 | PubTator's text mining | https://conductscience.org/library/genes/290 | NCBI Gene |
| ANXA1 | 301 | PubTator's text mining | https://conductscience.org/library/genes/301 | NCBI Gene |
| AQP5 | 362 | PubTator's text mining | https://conductscience.org/library/genes/362 | NCBI Gene |
| AZU1 | 566 | PubTator's text mining | https://conductscience.org/library/genes/566 | NCBI Gene |
| CALML3 | 810 | PubTator's text mining | https://conductscience.org/library/genes/810 | NCBI Gene |
1 to 10 of 78
See all 78 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41789112
GET https://conductscience.org/api/papers/v1/41789112/references?page=2